Exelixis (EXEL)
(Delayed Data from NSDQ)
$23.70 USD
+0.17 (0.72%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $23.70 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Exelixis (EXEL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$27.28 | $32.00 | $19.00 | 15.94% |
Price Target
Based on short-term price targets offered by 18 analysts, the average price target for Exelixis comes to $27.28. The forecasts range from a low of $19.00 to a high of $32.00. The average price target represents an increase of 15.94% from the last closing price of $23.53.
Analyst Price Targets (18)
Broker Rating
Exelixis currently has an average brokerage recommendation (ABR) of 1.47 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 19 brokerage firms. The current ABR compares to an ABR of 1.37 a month ago based on 19 recommendations.
Of the 19 recommendations deriving the current ABR, 14 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 73.68% and 5.26% of all recommendations. A month ago, Strong Buy made up 78.95%, while Buy represented 5.26%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 14 | 14 | 15 | 15 | 15 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 4 | 4 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.47 | 1.47 | 1.37 | 1.37 | 1.37 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/10/2024 | JMP Securities | Silvan C Tuerkcan | Strong Buy | Strong Buy |
2/26/2024 | Truist Securities | Asthika S Goonewardene | Strong Buy | Strong Buy |
2/22/2024 | SVB Securities | Andrew Berens | Not Available | Hold |
2/7/2024 | Piper Sandler | Joseph M Catanzaro | Strong Buy | Strong Buy |
1/8/2024 | William Blair | Andy T Hsieh | Strong Buy | Strong Buy |
12/19/2023 | BTIG | Kaveri Pohlman | Not Available | Strong Buy |
10/11/2023 | Guggenheim Securities | Michael Schmidt | Strong Buy | Strong Buy |
9/26/2023 | H.C. Wainwright & Co. | Robert Burns | Not Available | Strong Buy |
9/1/2023 | BMO Capital Markets | Etzer Darout | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.47 |
ABR (Last week) | 1.47 |
# of Recs in ABR | 19 |
Average Target Price | $27.28 |
LT Growth Rate | 31.10% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | 0.28 |